Celgene Corp. (CELG)

98.95
0.28 0.28
NASDAQ : Health Technology
Prev Close 98.67
Open 98.55
Day Low/High 98.45 / 99.33
52 Wk Low/High 58.59 / 99.36
Volume 2.17M
Avg Volume 3.81M
Exchange NASDAQ
Shares Outstanding 708.74M
Market Cap 69.88B
EPS 5.70
P/E Ratio 13.51
Div & Yield N.A. (N.A)
Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

Video: Jim's Daily Rundown for Thursday

Jim discusses Thursday's market selloff, what Apple's preannouncement means for the stock long term, the announced Bristol-Myers Squibb acquisition of Celgene and how it relates to Amgen, the oil market, and much more!

Jim Cramer's Thoughts on Bristol-Myers Deal

Jim Cramer's Thoughts on Bristol-Myers Deal

Jim Cramer's thoughts on Bristol-Myers and how it sets the stage for mergers and acquisitions going into 2019.

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.

Is Bristol-Myers Paying Too Much for Celgene?

Is Bristol-Myers Paying Too Much for Celgene?

BMY agreed to acquire CELG for $74 billion in cash and stock.

Why Jim Cramer Is Worried About Bristol-Myers Bid to Buy Celgene

Why Jim Cramer Is Worried About Bristol-Myers Bid to Buy Celgene

Jim Cramer's thoughts on the Bristol-Myers deal and Apple's issues with China.

Searching for Signs of Bottoming Action

Searching for Signs of Bottoming Action

The big problem this market faces technically is that there isn't much support down to the lows hit on Dec. 24.

Jim Cramer: Bristol-Myers, Apple, and the Markets

Jim Cramer: Bristol-Myers, Apple, and the Markets

Jim Cramer's back and ready to tackle the Bristol-Myers Celgene deal, Apple and the markets.

Bristol-Myers Squibb To Acquire Celgene To Create A Premier Innovative Biopharma Company

Bristol-Myers Squibb To Acquire Celgene To Create A Premier Innovative Biopharma Company

Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG) today announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity...

New Year's Investing Resolutions

New Year's Investing Resolutions

The market's day-to-day extreme volatility tested even the most seasoned investors. Adhering to portfolio principles can help.

Celgene Corporation To Present At The 37th Annual J.P. Morgan Healthcare Conference

Celgene Corporation To Present At The 37th Annual J.P. Morgan Healthcare Conference

Celgene Corporation (NASDAQ:CELG) will present a business update and provide 2019 financial guidance at the 37 th Annual J.

Celgene Corporation Announces Celgene Cancer Care Links™ Program Grant Recipients

Celgene Corporation Announces Celgene Cancer Care Links™ Program Grant Recipients

Celgene Corporation (NASDAQ:CELG) today announced ten programs selected for funding under its Celgene Cancer Care Links™ program, an initiative designed to support cancer healthcare capacity building in resource-constrained countries around the world.

A Way to Exploit Algorithm-Induced Market Swings When Trading Biotech Issues

A Way to Exploit Algorithm-Induced Market Swings When Trading Biotech Issues

It can be disturbing to see various names lose value quickly on no news, but here is a method to take advantage of such moves.

Celgene Corporation Announces Initial Clinical Data From Ongoing Phase 1/2 Evolve Trial With Anti-BCMA CAR T Therapy JCARH125 In Relapsed/Refractory Multiple Myeloma At ASH 2018

Celgene Corporation Announces Initial Clinical Data From Ongoing Phase 1/2 Evolve Trial With Anti-BCMA CAR T Therapy JCARH125 In Relapsed/Refractory Multiple Myeloma At ASH 2018

Celgene Corporation (NASDAQ:CELG) today announced initial safety data from its ongoing proof-of-concept trial of JCARH125 in patients with relapsed/refractory multiple myeloma.

Celgene Corporation Announces Results Of AUGMENT Evaluating REVLIMID® In Combination With Rituximab (R2) In Patients With Relapsed/Refractory Indolent Lymphoma At ASH 2018

Celgene Corporation Announces Results Of AUGMENT Evaluating REVLIMID® In Combination With Rituximab (R2) In Patients With Relapsed/Refractory Indolent Lymphoma At ASH 2018

Celgene Corporation (NASDAQ: CELG) today announced results of the phase 3 AUGMENT study, which showed that REVLIMID ® (lenalidomide) in combination with rituximab (R 2) demonstrated superior progression-free survival (PFS) in patients with...

Bluebird Bio And Celgene Corporation Present Initial Data From Ongoing Phase 1 Clinical Study Of Next-Generation Anti-BCMA CAR T Cell Therapy Bb21217 In Patients With Relapsed/Refractory Multiple Myeloma At ASH Annual Meeting

Bluebird Bio And Celgene Corporation Present Initial Data From Ongoing Phase 1 Clinical Study Of Next-Generation Anti-BCMA CAR T Cell Therapy Bb21217 In Patients With Relapsed/Refractory Multiple Myeloma At ASH Annual Meeting

bluebird bio, Inc. (Nasdaq:BLUE) and Celgene Corporation (NASDAQ:CELG) announced initial data from the ongoing Phase 1 clinical study of bb21217 (CRB-402), an investigational next-generation anti-BCMA CAR T cell therapy being studied in patients with...

Celgene Corporation And Acceleron Pharma Announce Results Of The Phase 3 MEDALIST Trial Evaluating Luspatercept In Patients With Myelodysplastic Syndromes At The ASH 2018 Plenary Session

Celgene Corporation And Acceleron Pharma Announce Results Of The Phase 3 MEDALIST Trial Evaluating Luspatercept In Patients With Myelodysplastic Syndromes At The ASH 2018 Plenary Session

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from the pivotal, phase 3 MEDALIST trial evaluating the efficacy and safety of investigational luspatercept to treat patients with ring sideroblast (RS+)...

Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data In Patients With Relapsed/Refractory CLL, Including Those With High-Risk Disease, Previously Treated With Ibrutinib, At ASH 2018

Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data In Patients With Relapsed/Refractory CLL, Including Those With High-Risk Disease, Previously Treated With Ibrutinib, At ASH 2018

Celgene Corporation (NASDAQ: CELG) today announced initial data from the dose-escalation part of an ongoing, open-label multicenter phase 1/2 study of investigational lisocabtagene maraleucel (liso-cel; JCAR017) in patients with relapsed/refractory...

Celgene Corporation And Acceleron Pharma Announce Results Of The Phase 3 BELIEVE Trial Evaluating Luspatercept In Adult Patients With Beta-Thalassemia At ASH 2018

Celgene Corporation And Acceleron Pharma Announce Results Of The Phase 3 BELIEVE Trial Evaluating Luspatercept In Adult Patients With Beta-Thalassemia At ASH 2018

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a pivotal, phase 3 trial (BELIEVE) evaluating the safety and efficacy of luspatercept for the treatment of adults with beta-thalassemia-associated...

2 Small Biotech Stocks That Insiders Are Buying

2 Small Biotech Stocks That Insiders Are Buying

Both names looked poised to go higher as soon as sentiment around the small biotech sector improves.

Celgene Is Showing Us a Couple of Interesting Bullish Divergences

Celgene Is Showing Us a Couple of Interesting Bullish Divergences

Celgene could be at a temporary low or it could be starting a new base pattern.

Celgene Corporation And Bluebird Bio Complete Enrollment Of Pivotal KarMMa Study Of Anti-BCMA Car T Cell Therapy Bb2121 In Patients With Relapsed And Refractory Multiple Myeloma

Celgene Corporation And Bluebird Bio Complete Enrollment Of Pivotal KarMMa Study Of Anti-BCMA Car T Cell Therapy Bb2121 In Patients With Relapsed And Refractory Multiple Myeloma

Celgene Corporation (Nasdaq: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced the completion of enrollment for the KarMMa pivotal study of bb2121, the companies' lead investigational anti-BCMA CAR T cell therapy candidate for patients with...

Classic Bear-Market Rally: Cramer's 'Mad Money' Recap (Monday 11/26/18)

Classic Bear-Market Rally: Cramer's 'Mad Money' Recap (Monday 11/26/18)

What comes next? Anything concrete to justify this rally? Sorry, says Jim Cramer. It's just a reprieve, not a sustainable turnaround.

Jim Cramer: I Can't Believe How Badly Many Huge, Important Stocks Have Performed

Jim Cramer: I Can't Believe How Badly Many Huge, Important Stocks Have Performed

I tire of hearing that there has been a correction.

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.

Here's How I'm Playing Biotech Now

Here's How I'm Playing Biotech Now

I continue to deploy 'dry powder' into the biotech sector on dips using Buy-Write option strategies.

Gridlock and Economic Slowing: Cramer's 'Mad Money' Recap (Tuesday 11/6/18)

Gridlock and Economic Slowing: Cramer's 'Mad Money' Recap (Tuesday 11/6/18)

Jim Cramer explains his post-election play book: Growth stocks may be the way to go.

Canada Goose, Celgene, BlackRock: 'Mad Money' Lightning Round

Canada Goose, Celgene, BlackRock: 'Mad Money' Lightning Round

Jim Cramer weighs in on Canada Goose, Celgene, BlackRock, Nio, Hospitality Property Trust, Activision Blizzard and more.

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.

Celgene Corporation To Webcast At Upcoming Investor Events

Celgene Corporation To Webcast At Upcoming Investor Events

Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor events where Celgene management will provide an overview of the Company.

TheStreet Quant Rating: C+ (Hold)